Skip to main content
. 2021 Aug 30;12:670862. doi: 10.3389/fphar.2021.670862

FIGURE 3.

FIGURE 3

Overview of the results from DDI studies of palbociclib combined with CYP3A inhibitors and inducers. The coloured symbols represent the increase or decrease in AUC caused by the interacting drug, expressed as adjusted mean ±90% confidence interval (if available). The dashed line represents the baseline AUC (Food and Drug Administration, 2014d; European Medicines Agency Committee for Medicinal Products For Human Use (CHMP), 2016b; Yu et al., 2017).